We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$846M
AUM Growth
+$95.3M
Cap. Flow
+$37.1M
Cap. Flow %
4.39%
Top 10 Hldgs %
28.99%
Holding
143
New
11
Increased
56
Reduced
23
Closed
11

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$7.11M
2
IART icon
Integra LifeSciences
IART
+$6.94M
3
CI icon
Cigna
CI
+$6.83M
4
ALKS icon
Alkermes
ALKS
+$5.7M
5
IQV icon
IQVIA
IQV
+$5.62M

Top Sells

Rank Stock Value
1
AKRX
Akorn Inc
AKRX
+$11.9M
2
CNC icon
Centene
CNC
+$9.33M
3
INCY icon
Incyte
INCY
+$8.09M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$6.18M
5
ALR
Alere Inc
ALR
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 92.73%
2 Financials 0.93%
3 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$34M 4.02%
261,992
+10,612
+4% +$1.3M
AMGN icon
2
Amgen
AMGN
$198B
$28.2M 3.33%
163,728
+8,278
+5% +$1.35M
MDT icon
3
Medtronic
MDT
$106B
$27.1M 3.21%
305,500
+63,000
+26% +$5.31M
UNH icon
4
UnitedHealth
UNH
$387B
$23.9M 2.83%
129,040
+5,100
+4% +$894K
ELV icon
5
Elevance Health
ELV
$80.9B
$23.2M 2.74%
123,347
+12,887
+12% +$2.32M
EW icon
6
Edwards Lifesciences
EW
$49.4B
$22.5M 2.66%
569,700
+194,700
+52% +$7.11M
ISRG icon
7
Intuitive Surgical
ISRG
$122B
$22.2M 2.62%
213,354
+16,029
+8% +$1.54M
GILD icon
8
Gilead Sciences
GILD
$167B
$22.1M 2.61%
311,803
+21,375
+7% +$1.42M
ABT icon
9
Abbott
ABT
$175B
$21.5M 2.55%
443,000
+37,500
+9% +$1.7M
ALGN icon
10
Align Technology
ALGN
$12.7B
$20.4M 2.42%
136,200
– –
ILMN icon
11
Illumina
ILMN
$28.2B
$18.8M 2.23%
111,502
+9,788
+10% +$1.69M
BSX icon
12
Boston Scientific
BSX
$65.4B
$17.4M 2.06%
628,000
+56,000
+10% +$1.49M
BIIB icon
13
Biogen
BIIB
$30.4B
$16.7M 1.97%
61,500
+8,000
+15% +$2.12M
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$15.5B
$15.6M 1.84%
100,203
-6,397
-6% -$978K
INCY icon
15
Incyte
INCY
$23.4B
$15.5M 1.84%
123,412
-63,538
-34% -$8.09M
LLY icon
16
Eli Lilly
LLY
$1.05T
$14.9M 1.76%
181,073
+49,673
+38% +$4.05M
WBA
17
DELISTED
Walgreens Boots Alliance
WBA
$14.6M 1.72%
185,872
+25,463
+16% +$2.1M
REGN icon
18
Regeneron Pharmaceuticals
REGN
$70.9B
$13.8M 1.63%
28,100
-1,200
-4% -$525K
CNC icon
19
Centene
CNC
$32.8B
$13.6M 1.6%
339,620
-247,060
-42% -$9.33M
BAX icon
20
Baxter International
BAX
$11.7B
$12.5M 1.47%
206,000
+16,000
+8% +$909K
HOLX
21
DELISTED
Hologic
HOLX
$12.4M 1.47%
273,423
-69,067
-20% -$3.05M
DHR icon
22
Danaher
DHR
$144B
$12.1M 1.43%
161,304
+32,712
+25% +$2.45M
ABMD
23
DELISTED
Abiomed Inc
ABMD
$12M 1.42%
83,970
+20,300
+32% +$2.73M
CI icon
24
Cigna
CI
$74.5B
$11.9M 1.41%
75,500
+42,500
+129% +$6.83M
BCR
25
DELISTED
CR Bard Inc.
BCR
$11.8M 1.39%
37,290
-11,140
-23% -$3.31M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2017 Portfolio in Review

As of Q2 2017, Bellevue Group held 143 positions worth $846M, up 13% from $750M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $37.1M of net new capital in Q2 2017, opening 11 new positions and adding to 56 existing holdings. Its largest new stake was IQVIA: 66,520 shares worth $5.95M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Centene, an estimated $9.33M trimmed.

  • Bellevue Group's largest Q2 2017 buy was IQVIA: 66,520 shares worth $5.95M.
  • Bellevue Group added most to Edwards Lifesciences in Q2 2017, an estimated $7.11M increase.
  • Bellevue Group's biggest Q2 2017 reduction was Centene, cutting an estimated $9.33M.
  • Bellevue Group fully exited Akorn Inc in Q2 2017, selling an estimated $11.9M.
  • Bellevue Group's ten largest holdings make up 29% of its $846M portfolio in Q2 2017.
  • Bellevue Group opened 11 new positions and closed 11 in Q2 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $846M.

Based on Bellevue Group's 13F filing for Q2 2017, filed 14 Aug 2017.